Aljohaney Ahmed A
Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Pulm Med. 2019 Jun 17;2019:6838439. doi: 10.1155/2019/6838439. eCollection 2019.
Here we present a comprehensive review of the literature concerning the utility of convex probe endobronchial ultrasound (CP-EBUS) in the diagnosis and treatment of nonmalignant conditions and discuss the associated complications. CP-EBUS has been conventionally used for the staging of lung cancer and sampling of mediastinal and hilar nodes. However, its application is not limited to malignant conditions, and it is gaining acceptance as a diagnostic modality of choice for nonmalignant conditions such as tuberculosis, sarcoidosis, pulmonary embolism, thyroid lesions, and cysts. Moreover, its therapeutic value allows for extended applications such as mediastinal and thyroid cyst drainage, fiducial marker placement for radiation therapy, and transbronchial needle injection. The noninvasiveness, low complication rate, high diagnostic yield, and satisfactory sensitivity and specificity values are the main attributes that lend credence to the use of CP-EBUS as a standalone primary diagnostic and therapeutic tool in pulmonary medicine in the foreseeable future.
在此,我们对有关凸阵探头支气管内超声(CP-EBUS)在非恶性疾病诊断和治疗中的应用的文献进行全面综述,并讨论相关并发症。CP-EBUS传统上用于肺癌分期以及纵隔和肺门淋巴结采样。然而,其应用并不局限于恶性疾病,并且它正逐渐被接受为用于诸如肺结核、结节病、肺栓塞、甲状腺病变和囊肿等非恶性疾病的首选诊断方式。此外,其治疗价值使得其应用得以扩展,如纵隔和甲状腺囊肿引流、放射治疗的基准标记放置以及经支气管针注射。无创性、低并发症发生率、高诊断率以及令人满意的敏感性和特异性值是在可预见的未来使CP-EBUS有理由作为肺病独立的主要诊断和治疗工具使用的主要特性。